http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104083430-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-481 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2014-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104083430-B |
| titleOfInvention | A kind of medicine for treating mink mycoplasma breathing problem |
| abstract | The present invention relates to a kind of medicine for treating mink mycoplasma breathing problem, belong to veterinary drug technical field.The medicine of the present invention is by 5 parts of lincomycin, 23 parts of ambroxol, 8 10 parts of the Radix Astragali, 78 parts of folium artemisiae argyi, 56 parts of dandelion, and surplus is prepared from for glucose.Although the Radix Astragali, folium artemisiae argyi, dandelion are independent or do not have therapeutic effect with the use of to mycoplasma breathing problem disease, but after being used cooperatively with lincomycin, ambroxol, cure rate to mink mycoplasma breathing problem disease is 91.5%, compared with lincomycin, its curative effect be improved significantly.In addition, the present invention obtains a kind of medicine of the higher treatment mink mycoplasma breathing problem of cure rate by further adding a small amount of totokaine and chlorpheniramine. |
| priorityDate | 2014-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.